IVDR Transition Extension (2024)

Regulation (EU) 2024/1860 amends Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) to prolong transitional periods for legacy devices certified or self‑declared under the former IVDD regime. It entered into force on 9 July 2024. The measure responds to persistent notified‑body capacity constraints and aims to prevent interruptions in the availability of critical diagnostics while maintaining a high level of health protection.

Under the amendment, sunset dates are staggered by IVDR risk class: Class D devices may continue under transitional provisions until 31 December 2027, Class C until 31 December 2028, and Class B and sterile Class A until 31 December 2029. These dates are not automatic entitlements. They apply only if manufacturers meet specific conditions, including timely steps toward IVDR certification and reinforced post‑market controls.

The extension keeps the IVDR’s overall structure and intent intact. It does not dilute conformity requirements, clinical evidence expectations, labeling rules, or unique device identification in the long term. Instead, it provides a pragmatic buffer so that dossiers, quality systems, and notified‑body assessments can be completed without destabilizing supply, aligning with the proportional, risk‑based ethos seen across EU product legislation.

For teams planning transitions, treat the new dates as a backstop and not a trigger to defer work. The practical workload—gap assessments, performance evaluation, analytical and clinical evidence generation, and QMS alignment—remains substantial. The Commission’s approach parallels the MDR extension framework and should be read together with your device’s specific classification and legacy status.

The extension covers legacy IVDs that were lawfully placed on the market under the IVDD and that fall into IVDR Classes D, C, B, or sterile Class A, provided they satisfy the conditions embedded in Regulation (EU) 2024/1860. Non‑sterile Class A devices are not part of the extension because they already fell under IVDR requirements without notified‑body involvement from the original date of application.

Eligibility hinges on continuity and control. Manufacturers must maintain valid legacy conformity (including certificates or declarations of conformity, as applicable) and preserve the device’s intended purpose and essential design characteristics. If changes amount to a significant change in design or intended purpose, the device can no longer rely on the transitional provisions and must comply with the IVDR in full upon that change.

Economic operators across the supply chain—authorized representatives, importers, and distributors—remain responsible for ensuring that only compliant legacy devices circulate during the transitional window. They must apply vigilance and market surveillance disciplines consistent with IVDR expectations, even while legacy conformity is recognized. Documentation, traceability, and incident response must be demonstrable and current.

A formal application to a notified body is central. Manufacturers seeking to benefit from the extension must submit a complete, good‑faith application for IVDR conformity assessment by the milestone dates set in the amending regulation and maintain progress toward a signed written agreement. The precise pathway depends on classification and conformity route, so teams should validate their classification under IVDR rules and reflect any reclassification impacts early.

The new sunset dates represent the last day legacy IVDD conformity may be used to place or make available covered devices, subject to compliance with the extension’s conditions. They are guardrails that secure continuity, not an invitation to pause IVDR work. Reaching an agreement with a notified body and advancing the technical documentation to IVDR standards are decisive milestones.

Two pillars determine eligibility over time. First, manufacturers must lodge a formal, complete application for IVDR conformity assessment with a notified body by the regulation’s specified milestones and progress to a written agreement. Second, they must maintain robust post‑market surveillance, vigilance, and registrational updates expected under the IVDR framework during the transitional period, while keeping legacy conformity valid and avoiding significant changes in design or intended purpose.

Notified‑body capacity remains a real constraint. Early engagement, clear classification rationale, and a realistic submission plan reduce the risk of missing milestones. Maintain continuous evidence generation and internal audits so that any conditions tied to post‑market performance and vigilance are verifiably met throughout the transition window.

Operationalizing the extension means running two tracks. One track preserves lawful legacy placement under IVDD while ensuring surveillance and vigilance meet IVDR expectations. The other track advances the IVDR technical documentation, performance evaluation, and QMS readiness through a notified‑body pathway. Governance must join these tracks so decisions on changes do not inadvertently void transitional status.

Notified‑body interactions should begin with validated classification, a mapped conformity route, and a dossier build plan. Expect capacity triage, document freezes, and structured rounds of questions. Evidence timing matters. Establish a realistic schedule for analytical and clinical performance studies and define acceptance criteria aligned to intended purpose and claimed indications.

Economic operators must document controls that ensure only eligible legacy lots are distributed and that label, IFU, and traceability data remain accurate. Vigilance must be tuned to IVDR thresholds for serious incidents and trend reporting, with clear escalation paths. Internal audits can test readiness and confirm PMS data streams function as intended.

• Confirm IVDR classification and conformity route, including any reclassification from IVDD.
• Perform a structured IVDR gap assessment covering technical documentation, PMS, and QMS.
• Submit a complete application to a notified body and track progress to a written agreement.
• Freeze significant design and intended‑purpose changes or run them through a formal impact assessment.
• Stage performance evaluation deliverables so responses to notified‑body questions are evidence‑based.
• Align PMS and vigilance to IVDR expectations and document sampling, trending, and CAPA decisions.

Even while marketing under legacy conformity, technical documentation must be built or upgraded to IVDR standards. Performance evaluation must integrate scientific validity, analytical performance, and clinical performance into a coherent plan and report. Claims, indications, and intended purpose require traceable evidence, with risk controls that are consistent with residual risks disclosed to users.

Risk management should follow state‑of‑the‑art principles aligned to ISO 14971 and its amendment, keeping a living risk file that reflects usability, software, biological safety, and cybersecurity where applicable. Using a structured risk matrix and a documented risk‑based validation strategy helps justify sampling, test depth, and verification focus as you answer notified‑body queries.

QMS alignment under Article 10 expectations benefits from an ISO 13485‑compliant system, with clear control of documents, records, training, supplier evaluation, and design controls. Digital QMS and document control reduce cycle time when iterating technical files, while periodic document review enforces currency for procedures and risk files.

Plan for traceability and vigilance evidence to be audited during the transition. Maintain PMS plans and reports that explain sampling logic, complaint trending, field safety corrective action criteria, and residual risk‑benefit justifications. Keep legacy and IVDR evidence strands reconcilable so you can demonstrate continuity of safety and performance assertions across the transition.

The most damaging errors stem from assuming the extension is automatic or that legacy products can be modified freely. The extension is conditional and closely tied to notified‑body engagement, stable intended purpose, and enhanced PMS. Misjudging any of these can force an unplanned full IVDR launch or result in loss of market access.

Classification deserves special attention. Under IVDR rules, many devices migrate to higher risk classes compared with IVDD. That changes the conformity route, the evidence burden, and the notified‑body modules you must pass. Align claims to intended purpose with care and resolve borderline interpretations early with documented rationales.

• Treating the extension as a grace period without filing a timely notified‑body application.
• Implementing design or intended‑purpose changes that constitute a significant change during transition.
• Underestimating performance evaluation depth for clinical performance and scientific validity.
• Neglecting IVDR‑level PMS, vigilance, and trend reporting while relying on legacy placement.
• Assuming non‑sterile Class A devices are covered by the extension when they are not.
• Failing to resource responses to notified‑body questions, leading to stalled assessments.

The IVDR extension echoes the MDR timetable relief adopted in 2023. While the structures are similar, class scopes, evidence expectations, and milestone dates differ. Organizations working across device and IVD portfolios should avoid cross‑applying MDR timelines to IVDR. Use the MDR framework as a governance template while anchoring decisions in IVDR classification and evidence rules.

Outside the EU, market access pathways continue to evolve. The United Kingdom is operating a staged UKCA medical device transition, with separate requirements and timelines. Switzerland and other non‑EU jurisdictions may adopt bridging measures or national guidance. Keep a register of jurisdictional deviations alongside your EU plan so labeling, vigilance, and technical file content remain accurate everywhere you ship.

International standards remain the backbone of an auditable approach. ISO 13485 supports QMS alignment and supplier control, while ISO 14971 governs risk management and benefit‑risk decisions. Software and data‑driven diagnostics should also track emerging obligations, including the EU AI Act for medical devices and IVD software, to ensure lifecycle controls extend beyond pure analytical performance.

In the United States, the FDA’s policy on laboratory developed tests and broader evidence expectations continue to shift. Multinational manufacturers should monitor FDA’s device program and harmonize dossier structures where possible. Cross‑referencing with the MDR extension regulation 2023/607 and maintaining consistent claims architecture across regions reduces rework and prevents divergence in intended purpose statements.

Treat the extension as a program with its own governance. Define clear accountabilities for classification, performance evaluation, PMS, and notified‑body interactions. A senior review board should arbitrate any change that could be significant in design or intended purpose and decide whether to proceed, defer, or accelerate IVDR launch. Evidence flow must be continuous and centrally visible.

Adopt a staged plan that front‑loads high‑risk gaps, especially for Class D and C devices. Build an integrated schedule connecting analytical and clinical work, documentation drafting, translations, labeling updates, and supplier qualifications. Use a risk matrix to prioritize and a living quality risk register to demonstrate control. Align validation depth to intended use with risk‑based validation.

Prepare for audits and inspections at any point during transition. Internal audits should test PMS trending, complaint handling, FSCA triggers, and CAPA effectiveness. Mock technical documentation reviews help teams measure responsiveness to common notified‑body questions. Ensure suppliers understand documentation and change‑control expectations, including sterilization evidence for sterile Class A.

Documentation hygiene is both a regulatory and a practical necessity. Keep a single source of truth for intended purpose, claims, risk controls, and labeling. Synchronize changes across technical documentation, PMS plans, and training to avoid inconsistencies that can stall notified‑body review. Regular reviews identify drift and ensure ongoing alignment with IVDR expectations during the transition.

Supplier control must support performance and sterility claims. Establish qualification dossiers for critical suppliers, define incoming inspection and sampling plans, and connect deviations to CAPA decisions. Digital tools that enforce version control and retrieval speed improve response time during audits and help demonstrate effective control of outsourced processes.

Inspection‑readiness remains a rolling objective. Maintain an audit calendar that includes internal, supplier, and notified‑body interactions. Use pre‑inspection walkthroughs to confirm complaint trending, vigilance thresholds, and FSCA playbooks are understood by cross‑functional teams. Close gaps with documented structured deviations and ensure leaders review outcomes during management review.

A disciplined cadence of periodic document review and targeted audit readiness checks helps ensure the evidence you compile today still withstands scrutiny months later. When coupled with proactive inspection readiness, organizations reduce risk of surprises and protect critical path milestones to IVDR certification.

Complex IVDR transitions demand real‑time visibility, disciplined change control, and fast, auditable document cycles. V5 Ultimate centralizes technical documentation, risk files, supplier records, and PMS evidence with role‑based workflows, traceability, and automated reminders. Teams move from static trackers to living dossiers that evolve with notified‑body feedback, reducing rework and cycle time.

Manufacturers use V5 to enforce harmonized procedures, lock intended‑purpose language, and connect changes to impact assessments that flag potential significance concerns. Integrated analytics give leaders a risk‑class view of progress against the Class D, C, and B/A sterile sunset dates, so resource and study plans can be adapted before bottlenecks form.

Supply chain controls strengthen evidence foundations. Approved supplier workflows, sampling plans, and deviation routing tie directly to CAPA and management review, supporting audit narratives. Notifications and tasking keep PMS trending and vigilance reporting on schedule throughout the transitional period.